Sellas Life Sciences Group Inc. surged after the drug developer reported positive late-stage trial results for an experimental cancer vaccine to treat an aggressive form of blood cancer.
Anonymous readers can preview up to 1024 characters here. Log in to unlock the full article once ingest succeeds.